Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
September 4th 2023Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.
Read More
Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC
August 31st 2023Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.
Read More
FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
August 28th 2023Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.
Read More
Camidge and Vokes Reflect on Research Journeys, Team Building, and Mentorship
August 24th 2023In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.
Read More
FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML
August 21st 2023Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.
Read More
Trent Breaks Down Mutation Testing and ctDNA Monitoring in GIST
August 17th 2023Dr Trent discusses the need for improved awareness around mutation testing in GIST, the limitations of current clinical trial criteria, and the potential for ctDNA to become a longitudinal cancer monitoring tool, helping to prevent invasive means of measuring disease progression.
Read More
Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
August 14th 2023Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why uproleselan could affect the treatment paradigm across AML subtypes, and the rationale for pursuing minimal residual disease negativity as a clinical end point in AML.
Read More
Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCINTIX biology-guided technology; and how John Theurer Cancer Center plans to use this technology and help advance its role in the field of radiation oncology.
Read More
FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
August 3rd 2023Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.
Read More
Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST
July 31st 2023Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and research seeking to expand the targeted therapy armamentarium.
Read More
Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL
July 24th 2023Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.
Read More
Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer
July 20th 2023Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.
Read More
FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
July 17th 2023Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.
Read More
Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management
July 13th 2023Dr Lunning sits down with Jeremy Abramson, MD, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.
Read More
FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
July 10th 2023Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.
Read More
King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer
July 6th 2023Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer and findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease.
Read More
Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
July 3rd 2023Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.
Read More
Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care
June 22nd 2023Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.
Read More
Investigators to Explore Potential of LP-300 With Chemo in Never Smokers With Advanced Lung Cancer
June 20th 2023Joshua Eric Reuss, MD, discusses the enrollment criteria for the HARMONIC trial, the demonstrated safety and efficacy of LP-300, and potential benefits of the agent for never smokers with advanced non–small cell lung cancer.
Read More
Strides in GI Cancer Subsets Influence Advances
June 20th 2023Tanios S. Bekaii-Saab, MD, highlights the unmet needs in GI malignancies and discusses how interdisciplinary meetings, such as the 20th Annual Meeting of the International Society of Gastrointestinal Oncology, provide the framework for disseminating information and driving innovative advances.
Read More
Reuss Reviews the Development of LP-300 in Advanced NSCLC
June 19th 2023Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.
Read More
FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
June 15th 2023Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.
Read More
FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
June 12th 2023Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.
Read More
Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
June 8th 2023Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.
Read More
Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology
June 5th 2023Dr Raskin discusses the road from fellow to fellowship director at Massachusetts General Hospital, the importance of transparency in a program amid increasing emphasis on health and wellness, and the skills a successful program should impart on their trainees.
Read More